EUVIMEDEUVIMED entdecken
Crossref

Farrerol alleviates microbiota dysbiosis-associated osteoporosis in IBD by inhibiting PI3K-AKT/MAPK signaling pathways

Ninglu Yin, Yuangang Su, Chaofeng Wang, Jiamin Liang, Tongtong Guo, Jinmin Zhao, Zemin Ling, Ren Xu, Qian Liu

Phytomedicine · 2025-11 · 148 · 157279

DOI: 10.1016/j.phymed.2025.157279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025-11. Verfasst von Ninglu Yin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed By the Province and Minis…. Hauptthemen laut MEDLINE: Osteoporosis, Dysbiosis, Gastrointestinal Microbiome, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Youth Science Foundation of Guangxi Medical University, Natural Science Foundation of Guangxi Zhuang Autonomous Region, Natural Science Foundation of Guangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: IBD, a global health concern, elevates osteoporosis risk primarily due to gut dysbiosis and chronic inflammation. While knowledge of the gut-bone axis advances, its exact mechanisms remain unclear, and effective treatments are still lacking. METHODS: In vivo, we assessed FA's effects on femoral bone mass in UC mice and analyzed gut microbiota changes via 16S rRNA sequencing. Metabolomics measured short-chain fatty acids to evaluate their role in bone loss. We performed RNA sequencing on femoral BMMs to identify FA-regulated genes and pathways. In vitro studies examined FA's mechanisms in inflammation and osteoclastogenesis using immunofluorescence, bone resorption assays, and molecular analyses. RESULTS: FA demonstrated significant protective effects against DSS-induced colitis. Specifically, it increased beneficial gut bacteria and short-chain fatty acid levels while reducing intestinal inflammation. Importantly, FA treatment reduced osteoclast-specific markers and inhibited nuclear translocation of key transcription factors. Moreover, FA suppressed bone resorption and osteoclastogenesis, thereby mitigating inflammatory bone remodeling. At the molecular level, FA exerted its protective effects by blocking PI3K-AKT and MAPK pathway activation, which subsequently inhibited osteoclast differentiation and function, ultimately preventing bone loss. CONCLUSIONS: This study demonstrated FA's protective effect against osteoporosis in UC mice through bone microstructure analysis and functional assays. FA reduced colonic inflammation and mucosal damage by modulating gut microbiota composition and fatty acid levels. These findings suggest FA mitigates bone loss by decreasing intestinal inflammation, improving gut flora, and suppressing osteoclast formation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisDysbiosisGastrointestinal MicrobiomeInflammatory Bowel DiseasesAnimalsMiceProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMice, Inbred C57BLMAP Kinase Signaling SystemMaleSignal TransductionOsteoclastsOsteogenesis

Stichwörter der Autor:innen

FarrerolGut microbiomeInflammatory bowel diseaseOsteoporosis

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed By the Province and Ministry, Guangxi Key Laboratory of Regenerative Medicine, The First Affili…

Förderung

  • Youth Science Foundation of Guangxi Medical University
  • Natural Science Foundation of Guangxi Zhuang Autonomous Region
  • Natural Science Foundation of Guangxi Province
  • National Natural Science Foundation of China

Zitieren

APA

Yin, N., Su, Y., Wang, C., Liang, J., Guo, T., Zhao, J., Ling, Z., Xu, R., & Liu, Q. (2025). Farrerol alleviates microbiota dysbiosis-associated osteoporosis in IBD by inhibiting PI3K-AKT/MAPK signaling pathways. Phytomedicine, 148, 157279. https://doi.org/10.1016/j.phymed.2025.157279

Vancouver

Yin N, Su Y, Wang C, Liang J, Guo T, Zhao J, et al. Farrerol alleviates microbiota dysbiosis-associated osteoporosis in IBD by inhibiting PI3K-AKT/MAPK signaling pathways. Phytomedicine. 2025;148:157279. doi:10.1016/j.phymed.2025.157279

BibTeX
@article{Yin2025,
  author = {Yin, Ninglu and Su, Yuangang and Wang, Chaofeng and Liang, Jiamin and Guo, Tongtong and Zhao, Jinmin and Ling, Zemin and Xu, Ren and Liu, Qian},
  title = {Farrerol alleviates microbiota dysbiosis-associated osteoporosis in IBD by inhibiting PI3K-AKT/MAPK signaling pathways},
  journal = {Phytomedicine},
  year = {2025},
  volume = {148},
  pages = {157279},
  doi = {10.1016/j.phymed.2025.157279}
}
Kostenlos starten →